Akari is targeting an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration in the first half of 2024 Composition of matter patent application filed on ...

BOSTON and LONDON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics—the first company dedicated to realizing the therapeutic potential of Serotonin Synthesis Amplification to treat central nervous ...

Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-owned Radio-DARPin therapeutics for imaging and therapeutic radio-isotopes, including Actinium-225 (225Ac) ZUR ...

Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics. But their complex structure poses significant development and safety challenges for biopharma. In this GEN webinar, ...

ACR246, a first in next-generation 5T4-ADC, as a potential choice of treating 5T4-positive solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

Channel Therapeutics announced successful pre-clinical results for its non-opioid pain treatment formulations, outperforming bupivacaine in efficacy and duration. Channel Therapeutics Corporation has ...

Newcells offers a range of physiologically-relevant and functionally-validated iPSC and primary-cell models to support drug developers de-risk pre-clinical decision-making and improve clinical ...

Cingulate Inc. completes FDA Pre-NDA meeting for ADHD drug CTx-1301 and secures $3 million grant for anxiety treatment CTx-2103. Cingulate Inc. announced the successful completion of a Pre-NDA meeting ...

AI-guided, synthetic lethal therapy achieves complete metabolic response after just two cycles in patient who failed three prior state-of-the-art treatment regimens. Complete response in an aggressive ...